

Larry W Moreland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9327888/publications.pdf>

Version: 2024-02-01

241
papers

39,463
citations

10650

74
h-index

3037

194
g-index

253
all docs

253
docs citations

253
times ranked

32293
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	0.9	2
2	Analysis of Complement Gene Expression, Clinical Associations, and Biodistribution of Complement Proteins in the Synovium of Early Rheumatoid Arthritis Patients Reveals Unique Pathophysiologic Features. <i>Journal of Immunology</i> , 2022, 208, 2482-2496.	0.4	9
3	A review of biosimilars for rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102234.	1.7	4
4	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	0.6	2
5	Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records. <i>Journal of Rheumatology</i> , 2021, 48, 1472-1479.	1.0	8
6	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i> . <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	2.9	34
7	Post-GWAS functional studies reveal an RA-associated <i>CD40</i> -induced NF- κ B signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors. <i>Human Molecular Genetics</i> , 2021, 30, 823-835.	1.4	4
8	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	0.9	21
9	Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. <i>PLoS ONE</i> , 2021, 16, e0244187.	1.1	16
10	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.4	3
11	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	0.9	33
12	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	1.0	20
13	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	1.5	77
14	Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 488-497.	1.3	2
15	Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. <i>Arthritis Care and Research</i> , 2020, 73, 1372-1378.	1.5	11
16	Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers. <i>Journal of Diagnostic Medical Sonography</i> , 2020, 36, 300-310.	0.1	0
17	B cells in rheumatoid arthritis synovial tissues encode focused antibody repertoires that include antibodies that stimulate macrophage TNF- α production. <i>Clinical Immunology</i> , 2020, 212, 108360.	1.4	12
18	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Transcriptional Regulation of CD40 Expression by 4 Ribosomal Proteins via a Functional SNP on a Disease-Associated CD40 Locus. <i>Genes</i> , 2020, 11, 1526.	1.0	4
20	Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug. <i>Arthritis Care and Research</i> , 2019, 71, 521-529.	1.5	24
21	Contraception Use Among Reproductive-Age Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2019, 71, 1132-1140.	1.5	22
22	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	1.6	43
23	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	2.9	64
24	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	0.9	37
25	Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. <i>Nature Immunology</i> , 2019, 20, 928-942.	7.0	760
26	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	1.0	6
27	Inflammatory joint diseases and atherosclerosis: time to look beyond the "lipid paradox". <i>Current Opinion in Lipidology</i> , 2019, 30, 342-349.	1.2	4
28	Pain and Catastrophizing in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 232-236.	0.5	8
29	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3-3 Methodology Applied to Two Active Comparator Trials. <i>Arthritis Care and Research</i> , 2019, 71, 319-322.	1.5	3
30	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	0.9	28
31	Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. <i>Arthritis Care and Research</i> , 2018, 70, 197-204.	1.5	65
32	Family Planning Counseling for Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2018, 70, 169-174.	1.5	28
33	14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in T C 2 and CD8 + lymphocytes from patients with scleroderma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 109-119.e6.	1.5	22
34	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	1.1	6
35	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. <i>Arthritis Research and Therapy</i> , 2018, 20, 139.	1.6	93
36	Update on Cardiovascular Disease Risk in Patients with Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 475-487.	0.8	32

#	ARTICLE	IF	CITATIONS
37	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	2.9	131
38	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	2.9	271
39	Persistence of Disease-associated Anti-Citrullinated Protein Antibody-expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission. <i>Arthritis and Rheumatology</i> , 2017, 69, 1176-1186.	2.9	34
40	Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study. <i>American Journal of Epidemiology</i> , 2017, 186, 245-254.	1.6	5
41	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	2.9	130
42	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
43	Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 46-57.	2.9	48
44	Cardiovascular Disease Risk in Patients with Rheumatic Diseases. <i>Clinics in Geriatric Medicine</i> , 2017, 33, 105-117.	1.0	17
45	Improvement in Herpes Zoster Vaccination in Patients with Rheumatoid Arthritis: A Quality Improvement Project. <i>Journal of Rheumatology</i> , 2017, 44, 11-17.	1.0	19
46	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e50.	2.1	24
47	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 98-101.	0.4	3
48	Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. <i>Arthritis Research and Therapy</i> , 2016, 18, 108.	1.6	48
49	Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatology</i> , 2016, 68, 577-586.	2.9	43
50	Analysis of CXCR5+Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis. <i>Scientific Reports</i> , 2016, 6, 39474.	1.6	17
51	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	5.8	73
52	Cost-effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1751-1757.	1.5	27
53	Socioeconomic factors and self-reported health outcomes in African Americans with rheumatoid arthritis from the Southeastern United States: the contribution of childhood socioeconomic status. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 10.	0.8	13
54	Reply. <i>Arthritis and Rheumatology</i> , 2016, 68, 555-556.	2.9	1

#	ARTICLE	IF	CITATIONS
55	Increased pretreatment serum IFN- γ ratio predicts non-response to tumour necrosis factor γ inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.5	59
56	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	1.6	109
57	Comprehensive Appraisal of Magnetic Resonance Imaging Findings in Sustained Rheumatoid Arthritis Remission: A Substudy. <i>Arthritis Care and Research</i> , 2015, 67, 929-939.	1.5	30
58	Rheumatoid Arthritis, Anti- γ -Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2311-2322.	2.9	69
59	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	1.0	87
60	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
61	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. <i>PLoS ONE</i> , 2014, 9, e87645.	1.1	34
62	Socioeconomic Disparities in the Health of African Americans With Rheumatoid Arthritis From the Southeastern United States. <i>Arthritis Care and Research</i> , 2014, 66, 1808-1817.	1.5	13
63	Complementary and Alternative Medicine Use in African Americans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 180-189.	1.5	26
64	Determinants of Mortality Among Postmenopausal Women in the Women's Health Initiative Who Report Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 497-507.	2.9	30
65	Induction Therapy with Combination TNF Inhibitor and Methotrexate in Early Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 417.	2.1	13
66	Rheumatoid Arthritis in the Women's Health Initiative: Methods and Baseline Evaluation. <i>American Journal of Epidemiology</i> , 2014, 179, 917-926.	1.6	11
67	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	13.7	1,974
68	Sedentary Behavior and Mortality in Older Women. <i>American Journal of Preventive Medicine</i> , 2014, 46, 122-135.	1.6	94
69	Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 785-786.	0.5	5
70	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 539-540.	6.7	0
71	Validation of the Methotrexate-First Strategy in Patients With Early, Poor-Prognosis Rheumatoid Arthritis: Results From a Two-Year Randomized, Double-Blind Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1985-1994.	6.7	62
72	Comparison of the Disease Activity Score Using Erythrocyte Sedimentation Rate and C-reactive Protein in African Americans with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1812-1822.	1.0	34

#	ARTICLE	IF	CITATIONS
73	Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. <i>Journal of Rheumatology</i> , 2013, 40, 787-797.	1.0	112
74	Changes in Lipoproteins Associated With Methotrexate Therapy or Combination Therapy in Early Rheumatoid Arthritis: Results From the Treatment of Early Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1430-1438.	6.7	124
75	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
76	Phenome-Wide Association Study (PheWAS) for Detection of Pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network. <i>PLoS Genetics</i> , 2013, 9, e1003087.	1.5	171
77	Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial. <i>Journal of Rheumatology</i> , 2013, 40, 572-578.	1.0	19
78	Predictive Value of Autoantibody Testing for Validating Self-reported Diagnoses of Rheumatoid Arthritis in the Women's Health Initiative. <i>American Journal of Epidemiology</i> , 2013, 177, 887-893.	1.6	7
79	Associations of Alcohol Use with Radiographic Disease Progression in African Americans with Recent-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1498-1504.	1.0	7
80	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013, 45, 468-469.	9.4	24
81	Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1804-1810.	1.5	17
82	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2824-2835.	6.7	325
83	Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women's Health Initiative Calcium plus Vitamin D trial. <i>Rheumatology International</i> , 2012, 32, 3823-3830.	1.5	30
84	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 625-639.	1.5	1,413
85	Impact of interactions of cigarette smoking with <i>NAT2</i> polymorphisms on rheumatoid arthritis risk in African Americans. <i>Arthritis and Rheumatism</i> , 2012, 64, 655-664.	6.7	26
86	Inhibition of Spleen Tyrosine Kinase for Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 377-378.	2.1	0
87	JAK Inhibition in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 379-380.	2.1	2
88	Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 381-382.	2.1	0
89	Radiographic severity of Rheumatoid Arthritis in African Americans: Results from a multicenter observational study. <i>Arthritis Care and Research</i> , 2010, 62, 624-631.	1.5	33
90	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95

#	ARTICLE	IF	CITATIONS
91	Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2219-2226.	6.7	28
92	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
93	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
94	A functional <i>RANKL</i> polymorphism associated with younger age at onset of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2864-2875.	6.7	35
95	Associations of cigarette smoking with rheumatoid arthritis in African Americans. <i>Arthritis and Rheumatism</i> , 2010, 62, 3560-3568.	6.7	44
96	Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. <i>Arthritis and Rheumatism</i> , 2010, 62, 3547-3553.	6.7	56
97	Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy. <i>Drug Design, Development and Therapy</i> , 2010, Volume 4, 263-278.	2.0	70
98	Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 625-626.	0.5	22
99	Certolizumab pegol: a new biologic targeting rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 855-866.	1.3	19
100	Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R75.	1.6	20
101	Vitamin D Status and Its Associations with Disease Activity and Severity in African Americans with Recent-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 275-281.	1.0	97
102	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
103	The Safety of Flavocoxid, a Medical Food, in the Dietary Management of Knee Osteoarthritis. <i>Journal of Medicinal Food</i> , 2009, 12, 1143-1148.	0.8	36
104	An African Ancestry-Specific Allele of CTLA4 Confers Protection against Rheumatoid Arthritis in African Americans. <i>PLoS Genetics</i> , 2009, 5, e1000424.	1.5	11
105	Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor Inhibitors. <i>Clinical Infectious Diseases</i> , 2009, 49, 924-927.	2.9	75
106	Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 132-143.	1.6	59
107	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009, 60, 1102-1111.	6.7	137
108	Golimumab, a human anti-tumor necrosis factor β monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2272-2283.	6.7	387

#	ARTICLE	IF	CITATIONS
109	Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. <i>Arthritis and Rheumatism</i> , 2009, 60, 2211-2215.	6.7	26
110	Methotrexate versus combination methotrexate and etanercept for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 309-310.	2.1	0
111	Certolizumab pegol in active rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 311-312.	2.1	1
112	Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 313-314.	2.1	1
113	REL, encoding a member of the NF- κ B family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. <i>Nature Genetics</i> , 2009, 41, 820-823.	9.4	305
114	Cytokines as Targets for Anti-inflammatory Agents. <i>Annals of the New York Academy of Sciences</i> , 2009, 1182, 88-96.	1.8	8
115	Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study. <i>Journal of Rheumatology</i> , 2009, 36, 736-742.	1.0	114
116	The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. <i>Arthritis and Rheumatism</i> , 2008, 58, 349-358.	6.7	77
117	Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. <i>Arthritis and Rheumatism</i> , 2008, 58, 953-963.	6.7	159
118	A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. <i>Arthritis and Rheumatism</i> , 2008, 58, 1810-1822.	6.7	99
119	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 762-784.	6.7	1,311
120	Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment failure gout: Results of a phase II randomized study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2882-2891.	6.7	156
121	Psoriatic arthritis: Current concepts on pathogenesis-oriented therapeutic options. <i>Arthritis and Rheumatism</i> , 2007, 56, 1051-1066.	6.7	53
122	Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. <i>Clinical Immunology</i> , 2007, 123, 235-243.	1.4	13
123	Long-Term Experience with Etanercept in the Treatment of Rheumatoid Arthritis in Elderly and Younger Patients. <i>Drugs and Aging</i> , 2006, 23, 167-178.	1.3	36
124	Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. <i>New England Journal of Medicine</i> , 2006, 354, 795-808.	13.9	1,127
125	Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2006, 144, 865.	2.0	643
126	Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 11-18.	0.9	9

#	ARTICLE	IF	CITATIONS
127	Abatacept. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 185-186.	21.5	158
128	Efficacy of costimulation blockade with abatacept in rheumatoid arthritis patients refractory to tumor necrosis factor- α inhibition. <i>Current Rheumatology Reports</i> , 2006, 8, 367-367.	2.1	0
129	Efficacy and safety of rituximab in rheumatoid arthritis patients refractory to methotrexate. <i>Current Rheumatology Reports</i> , 2006, 8, 368-368.	2.1	0
130	Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 55, 287-293.	6.7	50
131	Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3057-3059.	6.7	31
132	Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. <i>Journal of Rheumatology</i> , 2006, 33, 854-61.	1.0	78
133	Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 2162-6.	1.0	71
134	Validation of American College of Rheumatology Classification Criteria for Knee Osteoarthritis Using Arthroscopically Defined Cartilage Damage Scores. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 197-201.	1.6	97
135	Effects of doxycycline on progression of osteoarthritis: Results of a randomized, placebo-controlled, double-blind trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 2015-2025.	6.7	249
136	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 2263-2271.	6.7	456
137	Humanized anti-interleukin-6 receptor antibody. <i>Current Rheumatology Reports</i> , 2005, 7, 381-381.	2.1	0
138	Febuxostat " Treatment for Hyperuricemia and Gout?. <i>New England Journal of Medicine</i> , 2005, 353, 2505-2507.	13.9	16
139	Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1245-1254.	1.4	39
140	B cell targeted therapy: a new approach to the treatment of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005, 7, S1.	1.6	1
141	Unmet needs in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005, 7, S2.	1.6	26
142	Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. <i>Journal of the National Medical Association</i> , 2005, 97, 1155-60.	0.6	40
143	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. <i>Journal of Rheumatology</i> , 2005, 32, 832-40.	1.0	107
144	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1232-42.	1.0	89

#	ARTICLE	IF	CITATIONS
145	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1007-1018.	1.9	27
146	How do we best measure the clinical benefit of a structure-modifying osteoarthritis drug?. <i>Osteoarthritis and Cartilage</i> , 2004, 12, 61-62.	0.6	3
147	High-dose versus low-dose γ -penicillamine in early diffuse systemic sclerosis trial: lessons learned. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 249-263.	1.6	49
148	Ultrasound detection of bone erosions in rheumatoid arthritis: a comparison to routine radiographs of the hands and feet. <i>Skeletal Radiology</i> , 2004, 33, 80-84.	1.2	75
149	Adalimumab in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 333-334.	2.1	4
150	Infliximab in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 334-335.	2.1	3
151	Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 1412-1419.	6.7	478
152	The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. <i>Arthritis and Rheumatism</i> , 2004, 50, 2750-2756.	6.7	163
153	Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. <i>Arthritis and Rheumatism</i> , 2004, 51, 933-940.	6.7	21
154	Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis. <i>Pharmacoeconomics</i> , 2004, 22, 39-53.	1.7	60
155	Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 2858-2868.	6.7	133
156	Biologic Therapies on the Horizon for Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2004, 10, S32-S39.	0.5	15
157	Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. <i>Journal of Rheumatology</i> , 2004, 31, 1532-7.	1.0	49
158	Etanercept and methotrexate combination in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 333.	2.1	1
159	Adalimumab in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 333-4.	2.1	5
160	Adalimumab, a fully human anti-tumor necrosis factor γ monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 35-45.	6.7	1,612
161	Domains of health-related quality of life important to patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 819-825.	6.7	35
162	Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis. <i>Drug Safety</i> , 2003, 26, 23-32.	1.4	40

#	ARTICLE	IF	CITATIONS
163	Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig. <i>New England Journal of Medicine</i> , 2003, 349, 1907-1915.	13.9	973
164	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. <i>Clinical Therapeutics</i> , 2003, 25, 1700-1721.	1.1	279
165	Upcoming biologic agents for the treatment of rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2003, 15, 226-263.	2.0	50
166	Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. <i>Journal of Rheumatology</i> , 2003, 30, 691-6.	1.0	66
167	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 927-935.	1.9	7
168	Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 614-624.	6.7	570
169	Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. <i>Arthritis and Rheumatism</i> , 2002, 46, 1470-1479.	6.7	354
170	Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1460-1469.	6.7	219
171	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. <i>Arthritis and Rheumatism</i> , 2002, 46, 1443-1450.	6.7	664
172	High-resolution ultrasound for the study of target joints in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1969-1970.	6.7	30
173	Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2002, 46, 2020-2028.	6.7	106
174	Glucocorticoids and rheumatoid arthritis: Back to the future?. <i>Arthritis and Rheumatism</i> , 2002, 46, 2553-2563.	6.7	88
175	Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 2983-2989.	6.7	194
176	Predicting outcomes in early rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2002, 4, 193-194.	2.1	2
177	Genetic Influences on Rheumatoid Arthritis in African Americans. <i>Immunologic Research</i> , 2002, 26, 015-026.	1.3	1
178	Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. <i>Arthritis Research</i> , 2001, 3, 247.	2.0	45
179	Early rheumatoid arthritis: a medical emergency?. <i>American Journal of Medicine</i> , 2001, 111, 498-500.	0.6	26
180	POTENTIAL BIOLOGIC AGENTS FOR TREATING RHEUMATOID ARTHRITIS. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 445-491.	0.8	17

#	ARTICLE	IF	CITATIONS
181	A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs. <i>Pharmacoeconomics</i> , 2001, 19, 715-728.	1.7	37
182	New Therapeutic Approaches to the Management of Rheumatoid Arthritis. <i>BioDrugs</i> , 2001, 15, 379-393.	2.2	17
183	Efficacy and Safety of Intraarticular Sodium Hyaluronate in Knee Osteoarthritis. <i>Clinical Orthopaedics and Related Research</i> , 2001, 385, 130-143.	0.7	132
184	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2001, 44, 653-661.	6.7	96
185	Demyelinating and neurologic events reported in association with tumor necrosis factor ? antagonism: By what mechanisms could tumor necrosis factor ? antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. <i>Arthritis and Rheumatism</i> , 2001, 44, 1977-1983.	6.7	296
186	Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. <i>Arthritis and Rheumatism</i> , 2001, 44, 1984-1992.	6.7	275
187	TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 75-84.	0.9	44
188	Recombinant Human Relaxin in the Treatment of Scleroderma. <i>Annals of Internal Medicine</i> , 2000, 132, 871.	2.0	220
189	Practice Pattern Variation Among Internal Medicine Specialists in the Prevention of Glucocorticoid-Induced Osteoporosis. <i>Journal of Clinical Rheumatology</i> , 2000, 6, 117-122.	0.5	17
190	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. <i>Arthritis and Rheumatism</i> , 2000, 43, 2445-2454.	6.7	252
191	Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. <i>Clinical Therapeutics</i> , 2000, 22, 128-139.	1.1	97
192	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1586-1593.	13.9	1,776
193	Title is missing!. <i>Arthritis Research</i> , 2000, 1, S47.	2.0	0
194	The treatment of rheumatoid arthritis: A review of recent clinical trials. <i>Current Rheumatology Reports</i> , 1999, 1, 135-138.	2.1	2
195	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension. <i>Arthritis and Rheumatism</i> , 1999, 42, 357-365.	6.7	78
196	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 1194-1203.	6.7	312
197	Specific Cyclooxygenase 2 Inhibitors: A New Choice of Nonsteroidal Anti-Inflammatory Drug Therapy. <i>Arthritis and Rheumatism</i> , 1999, 12, 351-362.	6.7	30
198	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2372-2380.	6.7	96

#	ARTICLE	IF	CITATIONS
199	Clinical and pharmacological experience with etanercept. Expert Opinion on Investigational Drugs, 1999, 8, 1443-1451.	1.9	11
200	Etanercept Therapy in Rheumatoid Arthritis. Annals of Internal Medicine, 1999, 130, 478.	2.0	1,176
201	Recent Advances in Anti-Tumour Necrosis Factor (TNF) Therapy in Rheumatoid Arthritis. BioDrugs, 1999, 11, 201-210.	2.2	6
202	THE USE OF ANALGESICS IN THE MANAGEMENT OF PAIN IN RHEUMATIC DISEASES. Rheumatic Disease Clinics of North America, 1999, 25, 153-191.	0.8	12
203	Inter-observer reliability of the arthroscopic quantification of chondropathy of the knee. Osteoarthritis and Cartilage, 1998, 6, 160-166.	0.6	62
204	T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides. Arthritis and Rheumatism, 1998, 41, 1919-1929.	6.7	73
205	SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR (p75) FUSION PROTEIN (ENBREL) AS A THERAPY FOR RHEUMATOID ARTHRITIS. Rheumatic Disease Clinics of North America, 1998, 24, 579-591.	0.8	63
206	T-CELL RECEPTOR PEPTIDE VACCINATION IN THE TREATMENT OF RHEUMATOID ARTHRITIS. Rheumatic Disease Clinics of North America, 1998, 24, 641-650.	0.8	11
207	PERIOPERATIVE USE OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDERGOING ORTHOPEDIC SURGERY. Rheumatic Disease Clinics of North America, 1997, 23, 981-993.	0.8	36
208	Vaccination Against Rheumatoid Arthritis. BioDrugs, 1997, 8, 87-95.	2.2	2
209	Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)â€‘Fc Fusion Protein. New England Journal of Medicine, 1997, 337, 141-147.	13.9	1,586
210	Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis and Rheumatism, 1997, 40, 397-409.	6.7	143
211	Health status response of rheumatoid arthritis to treatment with DAB486IL-2. Arthritis and Rheumatism, 1996, 9, 112-119.	6.7	7
212	The Use of Methotrexate Perioperatively in Patients with Rheumatoid Arthritis Undergoing Major Joint Replacement Surgery. Journal of Clinical Rheumatology, 1996, 2, 6-8.	0.5	10
213	Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis and Rheumatism, 1996, 39, 257-265.	6.7	101
214	Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. Arthritis and Rheumatism, 1996, 39, 1172-1177.	6.7	77
215	ASSESSMENT OF NEEDLE ARTHROSCOPY. Journal of Clinical Rheumatology, 1995, 1, 255.	0.5	0
216	Synovial Biopsy of the Knee Joint under Direct Visualization by Needle Arthroscopy. Journal of Clinical Rheumatology, 1995, 1, 103-109.	0.5	8

#	ARTICLE	IF	CITATIONS
217	Improved methotrexate patient information. <i>Arthritis and Rheumatism</i> , 1995, 38, 874-875.	6.7	1
218	Interleukin-2 diphtheria fusion protein (dab486il-2) in refractory rheumatoid arthritis a double-blind, placebo-controlled trial with open-label extension. <i>Arthritis and Rheumatism</i> , 1995, 38, 1177-1186.	6.7	62
219	Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-cd4 antibody, cm-t412, in rheumatoid arthritis patients receiving concomitant methotrexate. <i>Arthritis and Rheumatism</i> , 1995, 38, 1581-1588.	6.7	107
220	Treatment of refractory rheumatoid arthritis with a chimeric ANTI-CD4 monoclonal antibody. <i>Arthritis and Rheumatism</i> , 1994, 37, 834-838.	6.7	118
221	Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 307-318.	6.7	134
222	New Approaches to the Therapy of Autoimmune Diseases: Rheumatoid Arthritis As a Paradigm. <i>American Journal of the Medical Sciences</i> , 1993, 305, 40-51.	0.4	12
223	Effects of Nonsteroidal Antiinflammatory Drugs on Bone Loss in Chronic Inflammatory Disease. <i>Annals of the New York Academy of Sciences</i> , 1993, 696, 292-302.	1.8	19
224	Transforming growth factor \hat{I}^2 within fibrotic scleroderma lungs. <i>American Journal of Medicine</i> , 1992, 93, 628-636.	0.6	23
225	Growth factors, extracellular matrix, and oncogenes in scleroderma. <i>Arthritis and Rheumatism</i> , 1992, 35, 304-310.	6.7	20
226	Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1991, 60, 412-418.	2.1	40
227	Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. <i>American Journal of Medicine</i> , 1991, 90, 295-298.	0.6	59
228	Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. <i>American Journal of Medicine</i> , 1991, 90, 295-298.	0.6	74
229	Rheumatoid arthritis patients and clinical drug trials A case-control study. <i>Arthritis and Rheumatism</i> , 1991, 4, 22-26.	6.7	7
230	Colchicine and gout. <i>Arthritis and Rheumatism</i> , 1991, 34, 782-786.	6.7	21
231	Achieving consensus on an algorithm for the treatment of rheumatoid arthritis with methotrexate. <i>Arthritis and Rheumatism</i> , 1990, 3, 53-57.	6.7	0
232	Cutaneous polyarteritis nodosa. <i>American Journal of Medicine</i> , 1990, 88, 426-430.	0.6	69
233	Inflammatory central nervous system involvement in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1989, 18, 258-266.	1.6	122
234	Spinal stenosis: A comprehensive review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 1989, 19, 127-149.	1.6	41

#	ARTICLE	IF	CITATIONS
235	Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. <i>Seminars in Arthritis and Rheumatism</i> , 1989, 19, 31-44.	1.6	63
236	Immunohistologic demonstration of type ii collagen in synovial fluid phagocytes of osteoarthritis and rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 1989, 32, 1458-1464.	6.7	23
237	Comment on the article by Furst et al. <i>Arthritis and Rheumatism</i> , 1989, 32, 1631-1632.	6.7	1
238	Intraarticular corticosteroid injections: Should we rest the joints?. <i>Arthritis and Rheumatism</i> , 1989, 2, 70-74.	6.7	34
239	Viral arthritis in humans. <i>Current Opinion in Rheumatology</i> , 1989, 1, 185-193.	2.0	0
240	Acute febrile neutrophilic dermatosis (sweet syndrome): A review of the literature with emphasis on musculoskeletal manifestations. <i>Seminars in Arthritis and Rheumatism</i> , 1988, 17, 143-155.	1.6	53
241	Ludwig's Angina. <i>Archives of Internal Medicine</i> , 1988, 148, 461.	4.3	85